Axsome Therapeutics, Inc. (AXSM)
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MoneyShow's Best Investment Ideas For 2026: Part 2
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Pharma Stock Soars to Record Highs on FDA Buzz
Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug.
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Sean Laaman - Morgan Stanley, Research Division Ashwani Verma - UBS Investment Bank, Research Division Lin Tsai - Jefferies LLC, Research Division Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Joon Lee - Truist Securities, Inc., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Dina Ramadane - BofA Securities, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division David Hoang - Deutsche Bank AG, Research Division Troy Langford - TD Cowen, Research Division Myles Minter - William Blair & Company L.L.C.
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating
Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi, with improving margins and narrowing net losses. AXSM faces risks from competition, regulatory hurdles, and high valuation, but maintains strong cash reserves and disciplined expense control.
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
